Clinical Trial Update: Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and tolerability of a novel A2A receptor agonist for diabetic neuropathic pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• A2A receptor agonist (experimental)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Diabetic Neuropathic Pain | Phase 2 | Status: COMPLETED